The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1677
ISSUE 1677
May 29, 2023
Issue 1677
- Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
- Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
- Cariprazine (Vraylar) for Adjunctive Treatment of Depression
- COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19
- COVID-19 Update: Metformin to Prevent Long Covid?
- Polatuzumab vedotin (Polivy) for Lymphoma (online only)
- Enfortumab Vedotin (Padcev) for Urothelial Cancer (online only)
- Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
May 29, 2023 (Issue: 1677)
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.